Emmaus Life Sciences, Inc. (OTCPK: EMMA), a California-based commercial-stage biopharmaceutical company involved in the treatment of sickle cell disease, announced on Wednesday its financial results for the year ended 31 December 2023.

The company reported net revenues for the year at USD29.6m, compared to USD18.4m for the year-ago period.

It reported operating expenses for the year at USD24.7m compared to USD22.4m in 2022.

The company reported net loss of USD3.7m or USD0.07 per share based on approximately 53.1 million weighted average basic common shares, against a net loss of USD10.6m or USD0.21 per share based on approximately 49.4 million weighted average basic and diluted common shares in 2022.